Literature DB >> 16261596

Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group.

Mary C Blandford1, Frederic G Barr, James C Lynch, R L Randall, Stephen J Qualman, Charles Keller.   

Abstract

BACKGROUND: Unresectable or metastatic disease represents the greatest obstacle to cure for children with rhabdomyosarcoma. In this study we sought to identify gene expression signatures of advanced stage and progressive disease. PROCEDURE: Using oligonucleotide gene expression analysis for a focused set of 60 genes, we analyzed the myogenic expression profiles of 89 rhabdomyosarcomas from the Intergroup Rhabdomyosarcoma Study-IV.
RESULTS: While the expression profile of rhabdomyosarcomas closely paralleled gene expression profiles of normal embryonic myogenic progenitors, growth factors were most closely associated with disease progression. Specifically, we identified platelet-derived growth factor (PDGF) receptors and insulin-like growth factor as strongly correlated with decreased failure-free survival. Real-time reverse transcriptase polymerase chain reaction (RT-PCR) of an independent data set suggested that autocrine growth signaling, if present, is not regulated in a simple manner at the transcriptional level.
CONCLUSIONS: Increased transcriptional levels of PDGF receptors and insulin-like growth factor are associated with decreased survival in rhabdomyosarcomas. Dual blockade of these growth-factor-signaling pathways may be a valuable strategy in preclinical therapeutic studies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16261596     DOI: 10.1002/pbc.20466

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  25 in total

Review 1.  Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature.

Authors:  Ossama M Maher; Soumen Khatua; Devashis Mukherjee; Adriana Olar; Alexander Lazar; Raja Luthra; Diane Liu; Jimin Wu; Leena Ketonen; Wafik Zaky
Journal:  J Neurooncol       Date:  2015-12-30       Impact factor: 4.130

2.  Targeted polytherapy in small cell sarcoma and its association with doxorubicin.

Authors:  S N Dumont; D Yang; A G Dumont; D Reynoso; J-Y Blay; J C Trent
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

3.  Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.

Authors:  Jinu Abraham; Suresh I Prajapati; Koichi Nishijo; Beverly S Schaffer; Eri Taniguchi; Aoife Kilcoyne; Amanda T McCleish; Laura D Nelon; Francis G Giles; Argiris Efstratiadis; Robin D LeGallo; Brent M Nowak; Brian P Rubin; Suman Malempati; Charles Keller
Journal:  Mol Cancer Ther       Date:  2011-03-29       Impact factor: 6.261

4.  The hedgehog regulated oncogenes Gli1 and Gli2 block myoblast differentiation by inhibiting MyoD-mediated transcriptional activation.

Authors:  A N Gerber; C W Wilson; Y-J Li; P-T Chuang
Journal:  Oncogene       Date:  2006-09-11       Impact factor: 9.867

5.  Zebrafish rhabdomyosarcoma reflects the developmental stage of oncogene expression during myogenesis.

Authors:  Narie Y Storer; Richard M White; Audrey Uong; Emily Price; G Petur Nielsen; David M Langenau; Leonard I Zon
Journal:  Development       Date:  2013-07       Impact factor: 6.868

Review 6.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

7.  PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma.

Authors:  E Taniguchi; K Nishijo; A T McCleish; J E Michalek; M H Grayson; A J Infante; H E Abboud; R D Legallo; S J Qualman; B P Rubin; C Keller
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

8.  Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.

Authors:  Kaiji Hu; Cathy Lee; Dexin Qiu; Abbas Fotovati; Alastair Davies; Samah Abu-Ali; Daniel Wai; Elizabeth R Lawlor; Timothy J Triche; Catherine J Pallen; Sandra E Dunn
Journal:  Mol Cancer Ther       Date:  2009-11-03       Impact factor: 6.261

9.  Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells.

Authors:  Mia Carapancea; Daria Cosaceanu; Raluca Budiu; Anna Kwiecinska; Ligia Tataranu; Vasile Ciubotaru; Oana Alexandru; Monica Banita; Catalina Pisoschi; Magnus L Bäcklund; Rolf Lewensohn; Anica Dricu
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

Review 10.  Diagnostic and prognostic sarcoma signatures.

Authors:  Elai Davicioni; Daniel H Wai; Michael J Anderson
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.